The potential utility of aripiprazole augmentation for major depressive disorder with mixed features specifier: A retrospective study

Changsu Han, Sheng Min Wang, Won Myong Bahk, Soo Jung Lee, Ashwin A. Patkar, Prakash S. Masand, Chi Un Pae

Research output: Contribution to journalArticle

Abstract

Objective: The present study aimed to observe potential benefit of aripiprazole augmentation in the treatment of major depressive disorder with mixed specifier (MDDM) in naturalistic treatment setting. Methods: Data were collected from MDDM patients using a retrospective chart review for 8 weeks (week-8 and week 0) in routine practice. All patients were on current antidepressants upon starting of aripiprazole. Patients were treated without restriction of doses of aripiprazole. The primary endpoint was the mean change of Montgomery-Åsberg Depression Rating Scale (MADRS) total scores along with various secondary endpoint measures. Results: In total 38 patients were analyzed. The changes of MADRS, Clinical Global Impression (CGI)-severity, Young Mania Rating Scale, Sheehan Disability Scale, and CGI-clinical benefit total scores from baseline to the endpoint were-7.1,-0.8,-4.9,-4.1, and-3.6, respectively (all p < 0.0001). At the endpoint, the responder and remitter rates by MADRS score criteria were approximately 32% and 21%, respectively. Conclusion: The present findings have clearly shown the effectiveness and tolerability of aripiprazole augmentation for MDDM patients in routine practice. The present study warrants subsequent, adequately-powered, well-controlled studies for generalizability near future.

Original languageEnglish
Pages (from-to)495-502
Number of pages8
JournalClinical Psychopharmacology and Neuroscience
Volume17
Issue number4
DOIs
Publication statusPublished - 2019 Jan 1

Keywords

  • Aripiprazole
  • Depressive disorder
  • Effectiveness
  • Mixed specifier
  • Tolerability

ASJC Scopus subject areas

  • Psychiatry and Mental health
  • Behavioral Neuroscience
  • Pharmacology (medical)

Cite this

The potential utility of aripiprazole augmentation for major depressive disorder with mixed features specifier : A retrospective study. / Han, Changsu; Wang, Sheng Min; Bahk, Won Myong; Lee, Soo Jung; Patkar, Ashwin A.; Masand, Prakash S.; Pae, Chi Un.

In: Clinical Psychopharmacology and Neuroscience, Vol. 17, No. 4, 01.01.2019, p. 495-502.

Research output: Contribution to journalArticle

Han, Changsu ; Wang, Sheng Min ; Bahk, Won Myong ; Lee, Soo Jung ; Patkar, Ashwin A. ; Masand, Prakash S. ; Pae, Chi Un. / The potential utility of aripiprazole augmentation for major depressive disorder with mixed features specifier : A retrospective study. In: Clinical Psychopharmacology and Neuroscience. 2019 ; Vol. 17, No. 4. pp. 495-502.
@article{104c87f2107442e991c2049e1ad8e504,
title = "The potential utility of aripiprazole augmentation for major depressive disorder with mixed features specifier: A retrospective study",
abstract = "Objective: The present study aimed to observe potential benefit of aripiprazole augmentation in the treatment of major depressive disorder with mixed specifier (MDDM) in naturalistic treatment setting. Methods: Data were collected from MDDM patients using a retrospective chart review for 8 weeks (week-8 and week 0) in routine practice. All patients were on current antidepressants upon starting of aripiprazole. Patients were treated without restriction of doses of aripiprazole. The primary endpoint was the mean change of Montgomery-{\AA}sberg Depression Rating Scale (MADRS) total scores along with various secondary endpoint measures. Results: In total 38 patients were analyzed. The changes of MADRS, Clinical Global Impression (CGI)-severity, Young Mania Rating Scale, Sheehan Disability Scale, and CGI-clinical benefit total scores from baseline to the endpoint were-7.1,-0.8,-4.9,-4.1, and-3.6, respectively (all p < 0.0001). At the endpoint, the responder and remitter rates by MADRS score criteria were approximately 32{\%} and 21{\%}, respectively. Conclusion: The present findings have clearly shown the effectiveness and tolerability of aripiprazole augmentation for MDDM patients in routine practice. The present study warrants subsequent, adequately-powered, well-controlled studies for generalizability near future.",
keywords = "Aripiprazole, Depressive disorder, Effectiveness, Mixed specifier, Tolerability",
author = "Changsu Han and Wang, {Sheng Min} and Bahk, {Won Myong} and Lee, {Soo Jung} and Patkar, {Ashwin A.} and Masand, {Prakash S.} and Pae, {Chi Un}",
year = "2019",
month = "1",
day = "1",
doi = "10.9758/cpn.2019.17.4.495",
language = "English",
volume = "17",
pages = "495--502",
journal = "Clinical Psychopharmacology and Neuroscience",
issn = "1738-1088",
publisher = "Korean College of Neuropsychopharmacology",
number = "4",

}

TY - JOUR

T1 - The potential utility of aripiprazole augmentation for major depressive disorder with mixed features specifier

T2 - A retrospective study

AU - Han, Changsu

AU - Wang, Sheng Min

AU - Bahk, Won Myong

AU - Lee, Soo Jung

AU - Patkar, Ashwin A.

AU - Masand, Prakash S.

AU - Pae, Chi Un

PY - 2019/1/1

Y1 - 2019/1/1

N2 - Objective: The present study aimed to observe potential benefit of aripiprazole augmentation in the treatment of major depressive disorder with mixed specifier (MDDM) in naturalistic treatment setting. Methods: Data were collected from MDDM patients using a retrospective chart review for 8 weeks (week-8 and week 0) in routine practice. All patients were on current antidepressants upon starting of aripiprazole. Patients were treated without restriction of doses of aripiprazole. The primary endpoint was the mean change of Montgomery-Åsberg Depression Rating Scale (MADRS) total scores along with various secondary endpoint measures. Results: In total 38 patients were analyzed. The changes of MADRS, Clinical Global Impression (CGI)-severity, Young Mania Rating Scale, Sheehan Disability Scale, and CGI-clinical benefit total scores from baseline to the endpoint were-7.1,-0.8,-4.9,-4.1, and-3.6, respectively (all p < 0.0001). At the endpoint, the responder and remitter rates by MADRS score criteria were approximately 32% and 21%, respectively. Conclusion: The present findings have clearly shown the effectiveness and tolerability of aripiprazole augmentation for MDDM patients in routine practice. The present study warrants subsequent, adequately-powered, well-controlled studies for generalizability near future.

AB - Objective: The present study aimed to observe potential benefit of aripiprazole augmentation in the treatment of major depressive disorder with mixed specifier (MDDM) in naturalistic treatment setting. Methods: Data were collected from MDDM patients using a retrospective chart review for 8 weeks (week-8 and week 0) in routine practice. All patients were on current antidepressants upon starting of aripiprazole. Patients were treated without restriction of doses of aripiprazole. The primary endpoint was the mean change of Montgomery-Åsberg Depression Rating Scale (MADRS) total scores along with various secondary endpoint measures. Results: In total 38 patients were analyzed. The changes of MADRS, Clinical Global Impression (CGI)-severity, Young Mania Rating Scale, Sheehan Disability Scale, and CGI-clinical benefit total scores from baseline to the endpoint were-7.1,-0.8,-4.9,-4.1, and-3.6, respectively (all p < 0.0001). At the endpoint, the responder and remitter rates by MADRS score criteria were approximately 32% and 21%, respectively. Conclusion: The present findings have clearly shown the effectiveness and tolerability of aripiprazole augmentation for MDDM patients in routine practice. The present study warrants subsequent, adequately-powered, well-controlled studies for generalizability near future.

KW - Aripiprazole

KW - Depressive disorder

KW - Effectiveness

KW - Mixed specifier

KW - Tolerability

UR - http://www.scopus.com/inward/record.url?scp=85075533316&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85075533316&partnerID=8YFLogxK

U2 - 10.9758/cpn.2019.17.4.495

DO - 10.9758/cpn.2019.17.4.495

M3 - Article

AN - SCOPUS:85075533316

VL - 17

SP - 495

EP - 502

JO - Clinical Psychopharmacology and Neuroscience

JF - Clinical Psychopharmacology and Neuroscience

SN - 1738-1088

IS - 4

ER -